声明:因水平有限,错误不可避免,或有些信息非最及时,欢迎留言指出。本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及);本文不构成任何投资建议。5月13日,诺诚健华(香港联交所代码:09969;上交所代码:688428)发布2025年第一季度财报,财报显示,第一季度总收入同比增长129.9%,达到3.8亿元,主要归功于核心产品奥布替尼(商品名:宜诺凯®)的持续放量以及公司与Prolium达成授权...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.